What You Should Know:
– Eli Lilly and Company announced positive topline Phase 3 results from ACHIEVE-1, a study evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes…
Continue Reading
Diet weight loss company Noom entered into an agreement with Eli Lilly’s LillyDirect pharmacy provider Gifthealth to help improve access to FDA-approved Zepbound (tirzepatide) single-dose vials for Noom’s members with an on-label prescription from…
Continue Reading
Hybrid weight-inclusive primary and metabolic care provider knownwell announced it will be listed as a care provider on pharma giant Eli Lilly’s digital healthcare platform LillyDirect.knownwell touts itself as a hybrid weight-inclusive provider offering primary…
Continue Reading
What You Should Know:
– Noom, a digital healthcare company focused on chronic disease prevention and empowering healthy living announced an agreement with Gifthealth, the LillyDirect® pharmacy provider of Eli Lilly and Company.
– The collaboration…
Continue Reading
What You Should Know:
– Teladoc Health, the global leader in virtual care announced a partnership with Gifthealth, a digital pharmacy platform and partner of Eli Lilly’s LillyDirect program, to improve access to tirzepatide (brand…
Continue Reading
Andreessen Horowitz (a16z) Bio + Health announced it is partnering with pharma giant Eli Lilly and Company to form a new venture capital fund, dubbed the Biotech Ecosystem Venture Fund.The aim of the fund…
Continue Reading
Pharmaceutical powerhouse Lilly Digital Health and Lilly Centre for Clinical Pharmacology (LCCP), a wholly owned subsidiary of Eli Lilly and Company, announced the creation of a SGD$42 million digital health innovation hub in Singapore.The…
Continue Reading
Top News
Drugmaker Eli Lilly sends letters to people who have taken compounding pharmacy versions of its Zepbound and Mounjaro weight loss drugs. It asks the the patients to authorize release of their medical records…
Continue Reading
What You Should Know:
– Eli Lilly’s Kisunla™ (donanemab-azbt) has been approved by the FDA as a treatment for adults in the early stages of Alzheimer’s disease (AD), including those with mild cognitive impairment (MCI)…
Continue Reading
What You Should Know:
– ALZpath, a leader in Alzheimer’s disease diagnostics, announced a licensing agreement with Roche for their innovative pTau217 antibody. This paves the way for a blood test to diagnose Alzheimer’s disease…
Continue Reading
